{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=33&state=Colorado", "query": { "state": "Colorado", "city": "Aurora", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 7441, "total_pages": 745, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=34&state=Colorado&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=32&state=Colorado&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T09:50:53.631Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05011058", "title": "An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epstein-Barr Virus Associated Lymphoma", "EBV-Positive DLBCL, NOS", "EBV-Related Non-Hodgkin Lymphoma", "EBV Related PTCL, NOS", "EBV-Related Hodgkin Lymphoma", "EBV-Related PTLD", "EBV-Related Lymphoproliferative Disorder" ], "interventions": [ { "name": "Nanatinostat in combination with valganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Viracta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2021-05-28", "completion_date": "2025-01-31", "has_results": true, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-11-06T09:50:53.631Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05011058" }, { "nct_id": "NCT03952585", "title": "De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Basaloid Squamous Cell Carcinoma", "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Oropharyngeal Squamous Cell Carcinoma", "Papillary Squamous Cell Carcinoma", "Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Image Guided Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 384, "start_date": "2019-10-09", "completion_date": "2026-12-11", "has_results": true, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-11-06T09:50:53.631Z", "location_count": 493, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03952585" }, { "nct_id": "NCT05932589", "title": "Neurophysiologic Biomarkers in Rett Syndrome", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rett Syndrome", "RTT", "Rett Syndrome, Atypical" ], "interventions": [ { "name": "EEG and Auditory and Visual Evoked Potentials (AEP and VEP)", "type": "OTHER" }, { "name": "Clinical assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "FEMALE", "summary": "1 Year to 18 Years · Female only" }, "enrollment_count": 222, "start_date": "2023-10-11", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-06T09:50:53.631Z", "location_count": 6, "location_summary": "Los Angeles, California • Aurora, Colorado • Brookline, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Brookline", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05932589" }, { "nct_id": "NCT00822120", "title": "S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Nonneoplastic Condition" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "ABVD regimen", "type": "DRUG" }, { "name": "BEACOPP regimen", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "procarbazine hydrochloride", "type": "DRUG" }, { "name": "vinblastine sulfate", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 371, "start_date": "2009-07", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-11-06T09:50:53.631Z", "location_count": 423, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00822120" }, { "nct_id": "NCT01270347", "title": "Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "MP-376 (Levofloxacin Solution for Inhalation)", "type": "DRUG" }, { "name": "TIS (Tobramycin Inhalation Solution)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 282, "start_date": "2011-01", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2024-12-13", "last_synced_at": "2026-11-06T09:50:53.631Z", "location_count": 99, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 86 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01270347" }, { "nct_id": "NCT01382758", "title": "Near Infrared Spectroscopy for the Detection of Acute Kidney Injury in Children Following Cardiac Surgery", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Kidney Injury", "Heart; Dysfunction Postoperative, Cardiac Surgery", "Children" ], "interventions": [], "intervention_types": [], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Day", "maximum_age": "4 Years", "sex": "ALL", "summary": "1 Day to 4 Years" }, "enrollment_count": 107, "start_date": "2011-07", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-11-06T09:50:53.631Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01382758" }, { "nct_id": "NCT05849168", "title": "High-Intensity Interval Training to Improve Symptoms of Deployment-Related Respiratory Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Occupational Exposure" ], "interventions": [ { "name": "Exercise training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2023-11-27", "completion_date": "2024-07-31", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-11-06T09:50:53.631Z", "location_count": 2, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05849168" }, { "nct_id": "NCT03978520", "title": "A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus (SLE)" ], "interventions": [ { "name": "Elsubrutinib", "type": "DRUG" }, { "name": "Placebo for elsubrutinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo for upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 341, "start_date": "2019-07-25", "completion_date": "2022-07-14", "has_results": true, "last_update_posted_date": "2023-07-21", "last_synced_at": "2026-11-06T09:50:53.631Z", "location_count": 47, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 40 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03978520" }, { "nct_id": "NCT00377182", "title": "A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "PEGASYS", "type": "DRUG" }, { "name": "RO5024048 1500mg", "type": "DRUG" }, { "name": "RO5024048 3000mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 107, "start_date": "2006-09", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-11-06T09:50:53.631Z", "location_count": 17, "location_summary": "La Jolla, California • Long Beach, California • Sacramento, California + 13 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00377182" }, { "nct_id": "NCT06976268", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Parkinson Disease" ], "interventions": [ { "name": "BHV-8000 10mg", "type": "DRUG" }, { "name": "BHV-8000 20 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 550, "start_date": "2025-05-28", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-11-06T09:50:53.631Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Sun City, Arizona • Irvine, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06976268" } ] }